Zevra Therapeutics, Inc.
ZVRA Healthcare Biotechnology
Zevra Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.5 million, up 350.9% from fiscal 2024. In the quarter to June 2026, revenue grew 53.3%, EPS fell 88.7%, free cash flow grew 670.9% and total debt rose 4.07%, each against the same quarter a year earlier.
Follow ZVRA
Zevra Therapeutics, Inc. (ZVRA) P/E ratio
As of 16 October 2026, Zevra Therapeutics, Inc. (ZVRA) trades at a P/E ratio of 10.5×. Over the past ten years it has ranged from 0.0× (September 2025) to 23.6× (October 2025); the current reading is higher than 95% of that period. That is above the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 6.5× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 15.1× | 232.02% |
| Mar 2026 | 4.5× | (30.49%) |
| Dec 2025 | 6.5× | (65.61%) |
| Sep 2025 | 19.0× | — |
| 24 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CLYM Climb Bio, Inc. compare | n/m |
| OLMA Olema Pharmaceuticals, Inc. compare | n/m |
| PHAT Phathom Pharmaceuticals, Inc. compare | n/m |
| SLDB Solid Biosciences Inc. compare | n/m |
| NVCT Nuvectis Pharma, Inc. compare | n/m |
| SLN Silence Therapeutics PLC Sponsored ADR compare | n/m |
| WVE WAVE Life Sciences Ltd. compare | n/m |
| CRMD CorMedix Inc compare | 3.0× |
| ZVRA Zevra Therapeutics, Inc. | 10.5× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)